|
humans |
51 |
|
adult |
38 |
|
female |
35 |
|
male |
35 |
|
middle aged |
29 |
|
aged |
27 |
|
covid-19 |
23 |
|
hong kong |
22 |
|
bronchiectasis |
21 |
|
prospective studies |
17 |
|
animals |
16 |
|
anti-bacterial agents - pharmacology |
16 |
|
antimicrobial resistance |
15 |
|
child, preschool |
14 |
|
microbial sensitivity tests |
14 |
|
viral load |
14 |
|
asthma |
13 |
|
epidemiology |
13 |
|
hong kong - epidemiology |
13 |
|
rhizopus microsporus |
13 |
|
species index: fungi |
13 |
|
copd |
12 |
|
drug resistance, bacterial |
12 |
|
lung - radiography |
12 |
|
population surveillance |
12 |
|
retrospective studies |
12 |
|
treatment outcome |
12 |
|
adolescent |
11 |
|
aged, 80 and over |
11 |
|
carrier state - microbiology |
11 |
|
risk factors |
11 |
|
airborne infection |
10 |
|
alanine transaminase - blood |
10 |
|
birds - virology |
10 |
|
case-control studies |
10 |
|
cell line |
10 |
|
cell line, tumor |
10 |
|
cell tropism |
10 |
|
chick embryo |
10 |
|
child |
10 |
|
dogs |
10 |
|
drug resistance |
10 |
|
h5n1 |
10 |
|
hospitalization |
10 |
|
influenza a virus, h1n1 subtype - immunology - isolation and purification - pathogenicity |
10 |
|
influenza a virus, h1n1 subtype - physiology |
10 |
|
influenza a virus, h5n1 subtype - physiology |
10 |
|
influenza h1n1 |
10 |
|
influenza in birds - virology |
10 |
|
influenza, human - mortality |
10 |
|
influenza, human - virology |
10 |
|
methicillin resistance |
10 |
|
pandemics |
10 |
|
patient admission - statistics and numerical data |
10 |
|
pseudomonas aeruginosa |
10 |
|
sequence analysis, dna |
10 |
|
swine - virology |
10 |
|
swine diseases - virology |
10 |
|
swine-origin |
10 |
|
temperature |
10 |
|
virus replication |
10 |
|
bacterial proteins - genetics |
9 |
|
bacteriological techniques - methods |
9 |
|
bioaerosols |
9 |
|
china |
9 |
|
dna, bacterial - genetics |
9 |
|
influenza vaccines - administration and dosage |
9 |
|
methicillin-resistant staphylococcus aureus |
9 |
|
molecular epidemiology |
9 |
|
myocardial infarction - mortality - prevention and control |
9 |
|
operating rooms |
9 |
|
plasmids |
9 |
|
pneumococcal vaccines - administration and dosage |
9 |
|
polymerase chain reaction |
9 |
|
severe acute respiratory syndrome |
9 |
|
staphylococcal infections - microbiology |
9 |
|
streptococcus pneumoniae |
9 |
|
stroke - mortality - prevention and control |
9 |
|
vaccination - methods |
9 |
|
algorithms |
8 |
|
antibiotic resistance |
8 |
|
antibodies, neutralizing - blood |
8 |
|
antibodies, viral - blood |
8 |
|
antibody response |
8 |
|
asymptomatic infection |
8 |
|
bacteremia - microbiology |
8 |
|
bacterial typing techniques |
8 |
|
biological markers - blood |
8 |
|
case study |
8 |
|
child day care centers |
8 |
|
cilia |
8 |
|
dna, bacterial - chemistry - genetics |
8 |
|
escherichia coli |
8 |
|
fatal outcome |
8 |
|
genes, bacterial |
8 |
|
immunocompromised host |
8 |
|
incidence |
8 |
|
influenza |
8 |
|
influenza a virus, h1n1 subtype - genetics - immunology - isolation and purification |
8 |
|
influenza, human - immunology - pathology - virology |
8 |
|
meticillin-resistant staphylococcus aureus |
8 |
|
mrsa |
8 |
|
nasopharynx - microbiology |
8 |
|
predictive value of tests |
8 |
|
rna, viral - genetics |
8 |
|
vancomycin resistance |
8 |
|
vancomycin-resistant enterococci |
8 |
|
antimicrobial drug resistance |
7 |
|
bronchiectasis - drug therapy |
7 |
|
cohort studies |
7 |
|
colistin |
7 |
|
community |
7 |
|
coronavirus disease 2019 |
7 |
|
coronavirus infection |
7 |
|
culture media - chemistry |
7 |
|
diarrhea - epidemiology - microbiology |
7 |
|
dna fingerprinting |
7 |
|
drug resistance, bacterial - genetics |
7 |
|
drug resistance, multiple, bacterial |
7 |
|
electrophoresis, gel, pulsed-field |
7 |
|
enterobacteriaceae |
7 |
|
hospitals |
7 |
|
infant |
7 |
|
klebsiella infections - epidemiology - microbiology |
7 |
|
klebsiella oxytoca - classification - genetics - isolation and purification - pathogenicity |
7 |
|
mcr-1 |
7 |
|
molnupiravir |
7 |
|
nose - microbiology |
7 |
|
pneumonia |
7 |
|
prevalence |
7 |
|
ribavirin - therapeutic use |
7 |
|
serotyping |
7 |
|
streptococcus pneumoniae - drug effects |
7 |
|
animals, domestic - microbiology |
6 |
|
antibiotics |
6 |
|
beta-lactamases - genetics |
6 |
|
biomedicine |
6 |
|
bone marrow transplantation - adverse effects |
6 |
|
bowel preparation |
6 |
|
candida tropicalis fungaemia |
6 |
|
china - epidemiology |
6 |
|
ciliary central microtubular orientation |
6 |
|
contact examination |
6 |
|
coronavirus |
6 |
|
corticosteroid |
6 |
|
daptomycin |
6 |
|
decolonization |
6 |
|
erythromycin |
6 |
|
escherichia coli infections - microbiology |
6 |
|
face mask |
6 |
|
fluoroquinolones |
6 |
|
fluoroquinolones - pharmacology |
6 |
|
follow-up studies |
6 |
|
forced expiratory volume - physiology |
6 |
|
genotype |
6 |
|
haematological malignancies |
6 |
|
health care workers |
6 |
|
heptavalent pneumococcal conjugate vaccine |
6 |
|
internal medicine |
6 |
|
lactobacillus rhamnosus gg |
6 |
|
linezolid |
6 |
|
mass vaccination |
6 |
|
medical microbiology |
6 |
|
medical sciences |
6 |
|
methicillin-resistant staphylococcus aureus - isolation and purification |
6 |
|
microbial sensitivity tests - methods |
6 |
|
molecular sequence data |
6 |
|
nosocomial transmission |
6 |
|
outbreak |
6 |
|
phenotype |
6 |
|
pneumococcal infections - microbiology |
6 |
|
pneumococcal vaccines |
6 |
|
polyethylene glycol |
6 |
|
polymorphism, restriction fragment length |
6 |
|
risk assessment |
6 |
|
sars-cov-2 |
6 |
|
severity of illness index |
6 |
|
spa type |
6 |
|
streptococcus pneumoniae - drug effects - immunology |
6 |
|
streptococcus pneumoniae - immunology |
6 |
|
time factors |
6 |
|
transmissibility |
6 |
|
transmission dynamics |
6 |
|
transmission electronic microscopy |
6 |
|
vaccines, conjugate |
6 |
|
administration, inhalation |
5 |
|
air sampling |
5 |
|
allogeneic stem cell transplantation |
5 |
|
amino acid sequence |
5 |
|
androstadienes - administration & dosage |
5 |
|
anti-bacterial agents |
5 |
|
anti-bacterial agents - therapeutic use |
5 |
|
anti-inflammatory agents - administration & dosage |
5 |
|
antibiotic susceptibility |
5 |
|
antifungal agents - therapeutic use |
5 |
|
antitubercular agents - pharmacology |
5 |
|
antiviral agents - therapeutic use |
5 |
|
aspergillosis - etiology |
5 |
|
aspergillus - isolation & purification |
5 |
|
bacterial toxins - genetics |
5 |
|
beta-lactam resistance - genetics |
5 |
|
beta-lactamases - biosynthesis - genetics |
5 |
|
beta-lactamases - chemistry - genetics |
5 |
|
blood cell count |
5 |
|
bone marrow transplantation |
5 |
|
caliciviridae infections - epidemiology - prevention and control - transmission |
5 |
|
carrier state - epidemiology - microbiology |
5 |
|
catheterization - adverse effects |
5 |
|
cattle |
5 |
|
chicken |
5 |
|
children |
5 |
|
chronic obstructive pulmonary disease |
5 |
|
clostridium difficile |
5 |
|
clostridium difficile - classification - genetics - isolation and purification |
5 |
|
cluster analysis |
5 |
|
colonization |
5 |
|
communicable diseases - classification |
5 |
|
cross infection - epidemiology - prevention and control - transmission |
5 |
|
cross infection - microbiology - prevention and control - transmission |
5 |
|
cross infection - prevention and control - transmission - virology |
5 |
|
ctx-m-14 beta-lactamase |
5 |
|
culture media |
5 |
|
dendritic cells - immunology - microbiology - virology |
5 |
|
diagnosis |
5 |
|
diagnosis, differential |
5 |
|
disease outbreaks - prevention and control - statistics and numerical data |
5 |
|
disease transmission, vertical - prevention & control |
5 |
|
drug resistance, microbial |
5 |
|
drug resistance, multiple, bacterial - genetics |
5 |
|
drug therapy, combination |
5 |
|
emergency service, hospital |
5 |
|
enterocolitis, pseudomembranous - epidemiology - microbiology |
5 |
|
environmental microbiology |
5 |
|
erythromycin - pharmacology |
5 |
|
escherichia coli - drug effects - genetics - metabolism |
5 |
|
exotoxins - genetics |
5 |
|
extended-spectrum beta-lactamases |
5 |
|
fasciitis, necrotizing - diagnosis - etiology - therapy |
5 |
|
fish diseases - microbiology |
5 |
|
food microbiology |
5 |
|
fusarium |
5 |
|
h1n1 virus |
5 |
|
handwashing - methods |
5 |
|
hematopoietic stem cell transplantation - adverse effects |
5 |
|
hiv infections - diagnosis - transmission |
5 |
|
hospitalization - statistics & numerical data |
5 |
|
immunosuppression - adverse effects |
5 |
|
infection control - methods |
5 |
|
infection control bundle |
5 |
|
influenza a virus, h1n1 subtype - immunology |
5 |
|
influenza a virus, h1n1 subtype - isolation and purification |
5 |
|
influenza, human - immunology |
5 |
|
influenza, human - prevention and control - transmission - virology |
5 |
|
inhaled corticosteroid therapy |
5 |
|
inpatients |
5 |
|
interstitial lung disease |
5 |
|
isoniazid - pharmacology |
5 |
|
kidney function tests |
5 |
|
leukocidins - genetics |
5 |
|
liver diseases - diagnosis - etiology |
5 |
|
logistic models |
5 |
|
masks |
5 |
|
mass screening - organization & administration |
5 |
|
methylprednisolone - administration & dosage |
5 |
|
molecular diagnostic techniques |
5 |
|
mycobacterium infections - etiology - microbiology |
5 |
|
mycobacterium tuberculosis |
5 |
|
mycobacterium tuberculosis - drug effects - genetics - isolation & purification |
5 |
|
nirmatrelvir-ritonavir |
5 |
|
nirmatrelvir–ritonavir |
5 |
|
nitric oxide |
5 |
|
nontuberculous mycobacterium |
5 |
|
norovirus - genetics - isolation and purification |
5 |
|
nosocomial infection |
5 |
|
ofloxacin - pharmacology |
5 |
|
patient isolation - methods |
5 |
|
pets |
5 |
|
pigs |
5 |
|
plasmid |
5 |
|
pneumococcal infections - immunology |
5 |
|
poultry |
5 |
|
prenatal diagnosis - methods |
5 |
|
primary prevention - organization & administration |
5 |
|
probability |
5 |
|
proteobacteria - enzymology - genetics |
5 |
|
pulse therapy, drug - methods |
5 |
|
referral and consultation |
5 |
|
respiratory tract infections - etiology - microbiology |
5 |
|
restriction fragment length polymorphism |
5 |
|
ribavirin |
5 |
|
ribotype 027 |
5 |
|
ribotyping |
5 |
|
rna, ribosomal, 16s - genetics |
5 |
|
sensitivity and specificity |
5 |
|
serotype |
5 |
|
severe acute respiratory syndrome - blood - complications - radiography |
5 |
|
severe acute respiratory syndrome - complications - diagnosis - metabolism |
5 |
|
severe acute respiratory syndrome - drug therapy |
5 |
|
staphylococcal infections - epidemiology - microbiology |
5 |
|
staphylococcal infections - microbiology - prevention and control - transmission |
5 |
|
staphylococcus aureus |
5 |
|
staphylococcus aureus - classification - drug effects - isolation & purification |
5 |
|
staphylococcus aureus - drug effects - genetics - isolation & purification |
5 |
|
statistics, nonparametric |
5 |
|
swine |
5 |
|
vaccine |
5 |
|
vital capacity |
5 |
|
acinetobacter - isolation & purification - metabolism |
4 |
|
acinetobacter baumannii |
4 |
|
acinetobacter-infections-epidemiology |
4 |
|
acinetobacter-isolation-and-purification |
4 |
|
acyl-coa dehydrogenase - genetics - metabolism |
4 |
|
aminoacyltransferases |
4 |
|
anti-infective agents - pharmacology |
4 |
|
antibiotic prophylaxis |
4 |
|
antibiotic sensitivity |
4 |
|
antibodies, bacterial - blood - immunology |
4 |
|
antigens, bacterial - genetics - immunology |
4 |
|
antitubercular agents - administration & dosage |
4 |
|
antivirulence |
4 |
|
aspartate aminotransferases - blood |
4 |
|
autophagy |
4 |
|
autophagy - genetics - immunology |
4 |
|
azithromycin - therapeutic use |
4 |
|
bacteraemia |
4 |
|
bacteremia - drug therapy - etiology - mortality |
4 |
|
bacteremia-epidemiology |
4 |
|
bacterial adherence |
4 |
|
bacterial adhesion - drug effects |
4 |
|
bacterial infection |
4 |
|
bacterial morphology |
4 |
|
bacterial pneumonia |
4 |
|
bacterium isolate |
4 |
|
base sequence |
4 |
|
beta-lactam resistance |
4 |
|
beta-lactamases - biosynthesis |
4 |
|
beta-lactamases - genetics - metabolism |
4 |
|
beta-lactamases - metabolism |
4 |
|
biological availability |
4 |
|
blood sampling |
4 |
|
body temperature |
4 |
|
bone marrow transplantation -immunology |
4 |
|
bronchiectasis - blood - etiology |
4 |
|
burkholderia pseudomallei - classification - genetics - immunology |
4 |
|
capping phenomenon |
4 |
|
carbapenem-resistant acinetobacter species |
4 |
|
carbapenemase-producing enterobacteriaceae |
4 |
|
carbapenemases |
4 |
|
carrier proteins - genetics |
4 |
|
carrier state |
4 |
|
cefotaxime/adverse effects |
4 |
|
cephalosporin |
4 |
|
cephalosporin resistance |
4 |
|
chi-square distribution |
4 |
|
children <5 years |
4 |
|
clinical laboratory |
4 |
|
cloaca - microbiology |
4 |
|
cloning, molecular |
4 |
|
clpp |
4 |
|
collagen - physiology |
4 |
|
colony count, microbial |
4 |
|
combination therapy |
4 |
|
community-acquired gastroenteritis |
4 |
|
community-acquired infections - microbiology |
4 |
|
conjugation, genetic |
4 |
|
contact tracing |
4 |
|
cross infection - epidemiology - microbiology |
4 |
|
cross infection - microbiology |
4 |
|
ctx-m-14 β-lactamase |
4 |
|
culture media, conditioned |
4 |
|
cystitis - microbiology |
4 |
|
day care centers |
4 |
|
debridement |
4 |
|
differential gene expression |
4 |
|
disease outbreaks |
4 |
|
disease surveillance |
4 |
|
disinfection |
4 |
|
dna gyrase - chemistry - genetics |
4 |
|
dose-response relationship, drug |
4 |
|
endemicity |
4 |
|
enzyme-linked immunosorbent assay |
4 |
|
esbl-producing enterobacterales |
4 |
|
escherichia coli - drug effects - enzymology - isolation & purification |
4 |
|
escherichia coli - enzymology - genetics - isolation & purification |
4 |
|
extended-spectrum beta-lactamase (esbl) |
4 |
|
extended-spectrum β-lactamases |
4 |
|
fade28 |
4 |
|
fever of unknown origin - microbiology - radiography |
4 |
|
fishes |
4 |
|
gastroenteritis - microbiology |
4 |
|
gastrointestinal colonization |
4 |
|
gene expression regulation, bacterial |
4 |
|
genes, bacterial - genetics |
4 |
|
glucose - metabolism |
4 |
|
gold |
4 |
|
graft rejection |
4 |
|
gram-positive bacterial infections - microbiology - veterinary |
4 |
|
haemophilus influenzae - drug effects |
4 |
|
heart rate |
4 |
|
hexosyltransferases - genetics |
4 |
|
hiv infections - genetics - metabolism |
4 |
|
hiv-1 - pathogenicity |
4 |
|
hiv-1 tat |
4 |
|
hypervirulent strain |
4 |
|
immunosuppressive agents - therapeutic use |
4 |
|
infection |
4 |
|
infectious diarrhoea |
4 |
|
interferon |
4 |
|
interferon-gamma - metabolism |
4 |
|
invasive pneumococcal disease |
4 |
|
is6110 |
4 |
|
ivig |
4 |
|
kidney transplantation - adverse effects |
4 |
|
klebsiella pneumoniae |
4 |
|
lung, infection |
4 |
|
macrolides - therapeutic use |
4 |
|
metalloenzymes |
4 |
|
methicillin resistance - genetics |
4 |
|
methicillin-resistant staphylococcus aureus - classification - drug effects - genetics - isolation and purification |
4 |
|
methicillin-resistant staphylococcus aureus - drug effects - isolation & purification |
4 |
|
microscopy, electron, scanning |
4 |
|
molecular diagnostic techniques - methods |
4 |
|
multidrug resistance |
4 |
|
multidrug-resistant organisms |
4 |
|
multilocus sequence typing |
4 |
|
muramoylpentapeptide carboxypeptidase - genetics |
4 |
|
mutation |
4 |
|
mutation - genetics - physiology |
4 |
|
mycobacterium tuberculosis - classification - genetics - metabolism - pathogenicity |
4 |
|
mycobacterium tuberculosis - drug effects - genetics |
4 |
|
mycobacterium tuberculosis - genetics |
4 |
|
mycoplasma pneumoniae - metabolism |
4 |
|
nalidixic acid - pharmacology |
4 |
|
nasal colonisation |
4 |
|
necrotizing fasciitis |
4 |
|
neisseriaceae - isolation & purification |
4 |
|
opportunistic infection |
4 |
|
opportunistic infections - diagnosis - immunology - microbiology |
4 |
|
oxidation-reduction |
4 |
|
oxygen - blood |
4 |
|
penicillin resistance - genetics |
4 |
|
penicillin-binding proteins |
4 |
|
peptidyl transferases - genetics |
4 |
|
peritoneal dialysis |
4 |
|
pneumococcal conjugate vaccine |
4 |
|
pneumococcal infections - epidemiology - microbiology |
4 |
|
pneumococcal infections/drug therapy |
4 |
|
pneumococcal vaccines - administration and dosage - immunology |
4 |
|
pneumonia - drug therapy - radiography |
4 |
|
polymerase chain reaction - methods |
4 |
|
pregnancy |
4 |
|
pregnancy complications, infectious - etiology - radiography |
4 |
|
proteus mirabilis - classification - drug effects - enzymology |
4 |
|
pseudomonas aeruginosa - drug effects - physiology |
4 |
|
rectum - microbiology |
4 |
|
renal transplant |
4 |
|
resistance |
4 |
|
restriction fragment length |
4 |
|
reverse transcriptase polymerase chain reaction - methods |
4 |
|
rodentia - microbiology |
4 |
|
screening |
4 |
|
serum |
4 |
|
severe acute respiratory syndrome (sars) |
4 |
|
severe acute respiratory syndrome - diagnosis - radiography - therapy |
4 |
|
shock, septic - diagnosis - etiology - therapy |
4 |
|
signal transduction - genetics - immunology |
4 |
|
silver |
4 |
|
skin diseases - microbiology - therapy |
4 |
|
sputum |
4 |
|
staphylococcus - drug effects |
4 |
|
streptococcus pneumoniae - classification - drug effects - isolation and purification |
4 |
|
streptococcus pneumoniae/drug effects |
4 |
|
streptococcus pyogenes |
4 |
|
subminimal inhibitory concentration |
4 |
|
tacrolimus |
4 |
|
tacrolimus - therapeutic use |
4 |
|
tomography, x-ray computed - methods |
4 |
|
transforming growth factor beta - metabolism |
4 |
|
transforming growth factor beta1 |
4 |
|
transforming growth factor-β1 |
4 |
|
tuberculin test |
4 |
|
tuberculoma - complications - radiography |
4 |
|
tuberculosis |
4 |
|
tuberculosis - diagnosis - microbiology |
4 |
|
tuberculosis, lymph node - diagnosis - drug therapy |
4 |
|
tuberculosis, meningeal - complications - radiography |
4 |
|
tuberculosis, meningeal - microbiology |
4 |
|
tuberculosis, miliary - diagnosis - drug therapy |
4 |
|
tuberculosis, multidrug-resistant - diagnosis - microbiology |
4 |
|
tuberculosis, pulmonary - diagnosis - microbiology |
4 |
|
up-regulation |
4 |
|
vancomycin |
4 |
|
vancomycin - pharmacology |
4 |
|
virulence factors |
4 |
|
virus |
4 |
|
β-lactams |
4 |
|
acinetobacter - drug effects - genetics - isolation and purification |
3 |
|
acinetobacter infections - epidemiology |
3 |
|
acute disease |
3 |
|
administration, oral |
3 |
|
administration, topical |
3 |
|
adrenal cortex hormones - therapeutic use |
3 |
|
air |
3 |
|
alleles |
3 |
|
amino acid substitution - genetics |
3 |
|
amoxicillin-potassium clavulanate combination |
3 |
|
amphotericin b - therapeutic use |
3 |
|
ampicillin resistance |
3 |
|
amplityping |
3 |
|
androstadienes - administration & dosage - therapeutic use |
3 |
|
anti-bacterial agents - pharmacology - therapeutic use |
3 |
|
anti-infective agents - administration & dosage - therapeutic use |
3 |
|
anti-inflammatory agents - administration & dosage - therapeutic use |
3 |
|
anti-virulence |
3 |
|
antibiotic control |
3 |
|
antibiotics, antitubercular - pharmacology |
3 |
|
antifungal agents |
3 |
|
antimicrobial resistance epidemiology |
3 |
|
antitubercular agents - therapeutic use |
3 |
|
aspergillosis - complications - drug therapy |
3 |
|
aspergillosis - diagnosis - drug therapy - etiology |
3 |
|
aspergillus - drug effects - growth & development |
3 |
|
attitude of health personnel |
3 |
|
attitudes |
3 |
|
atypical pneumonia |
3 |
|
bacteremia - diagnosis |
3 |
|
bacteremia - epidemiology - microbiology |
3 |
|
bacteremia - epidemiology - prevention & control |
3 |
|
bacterial infections - diagnosis - drug therapy |
3 |
|
bacterial proteins - metabolism |
3 |
|
bacteriological techniques |
3 |
|
bacterium examination |
3 |
|
bacteriuria - epidemiology - microbiology |
3 |
|
barriers |
3 |
|
behavior |
3 |
|
behaviour |
3 |
|
beta-lactamases |
3 |
|
beta-lactamases - analysis - antagonists & inhibitors |
3 |
|
beta-lactamases - analysis - genetics |
3 |
|
beta-lactams |
3 |
|
binary toxin |
3 |
|
binding sites |
3 |
|
blood culture |
3 |
|
bone marrow transplantation - immunology |
3 |
|
border restriction |
3 |
|
brain - microbiology |
3 |
|
bronchiectasis - drug therapy - immunology - microbiology - pathology |
3 |
|
burkholderia pseudomallei - drug effects |
3 |
|
burkholderia pseudomallei - enzymology - genetics - isolation & purification |
3 |
|
ca-mrsa |
3 |
|
candida - pathogenicity |
3 |
|
candida albicans - pathogenicity |
3 |
|
candidiasis, oral - immunology - microbiology - pathology |
3 |
|
carbapenem resistance |
3 |
|
carbapenemase |
3 |
|
carrier state - immunology - microbiology - pathology |
3 |
|
catalase - genetics |
3 |
|
catheters, indwelling - microbiology |
3 |
|
ceftazidime |
3 |
|
ceftazidime - administration & dosage - therapeutic use |
3 |
|
ceftazidime - blood - pharmacology - urine |
3 |
|
ceftazidime - metabolism |
3 |
|
ceftriaxone - blood - pharmacology - urine |
3 |
|
cephalosporin resistance - genetics |
3 |
|
cephalosporinase - genetics |
3 |
|
cephalosporins - administration & dosage - therapeutic use |
3 |
|
chemicals and cas registry numbers |
3 |
|
chest x-ray |
3 |
|
chinese |
3 |
|
clinical presentation |
3 |
|
clostridioides difficile |
3 |
|
co-trimoxazole |
3 |
|
communicable disease |
3 |
|
communicable diseases |
3 |
|
community-acquired infections |
3 |
|
community-acquired infections - drug therapy - microbiology |
3 |
|
community-acquired infections - epidemiology - microbiology |
3 |
|
community-acquired pneumonia |
3 |
|
comparative genomic analysis |
3 |
|
comparative genomic hybridization |
3 |
|
coronavirus disease 2019 (covid-19) |
3 |
|
cotrimoxazole resistance |
3 |
|
ctx-m enzymes |
3 |
|
cyclophosphamide |
3 |
|
cystitis - epidemiology - microbiology |
3 |
|
cytokines |
3 |
|
cytokines - biosynthesis - genetics - secretion |
3 |
|
dematiaceous fungi |
3 |
|
diagnostic |
3 |
|
diagnostic errors |
3 |
|
diagnostic test |
3 |
|
direct detection |
3 |
|
directly observed |
3 |
|
directly observed hand hygiene |
3 |
|
disease burden |
3 |
|
disease models, animal |
3 |
|
disk diffusion |
3 |
|
disseminated ochroconis gallopavum |
3 |
|
dna primers |
3 |
|
dna, bacterial - analysis |
3 |
|
dna-directed rna polymerases - chemistry - genetics |
3 |
|
drug therapy, combination - administration & dosage |
3 |
|
drug therapy, combination - therapeutic use |
3 |
|
drug utilization - standards |
3 |
|
drug-resistant tb |
3 |
|
electronics - instrumentation - methods - organization and administration |
3 |
|
empyema |
3 |
|
enablers |
3 |
|
encephalitis, herpes simplex - complications - immunology |
3 |
|
endocarditis - drug therapy - etiology - microbiology |
3 |
|
enterobacter - enzymology |
3 |
|
enterobacteriaceae - drug effects - genetics |
3 |
|
enterobacteriaceae infections - epidemiology - metabolism |
3 |
|
enterococcus - drug effects |
3 |
|
enterococcus faecium - growth & development - pathogenicity |
3 |
|
environmental hygiene |
3 |
|
enzyme inhibitors - pharmacology |
3 |
|
epidemic |
3 |
|
esbls |
3 |
|
escherichia coli - drug effects - enzymology |
3 |
|
escherichia coli - drug effects - enzymology - isolation and purification |
3 |
|
escherichia coli - drug effects - genetics |
3 |
|
escherichia coli - enzymology |
3 |
|
escherichia coli - enzymology - isolation & purification |
3 |
|
escherichia coli - growth & development - isolation & purification |
3 |
|
escherichia coli infections - epidemiology - microbiology |
3 |
|
exacerbations |
3 |
|
extended-spectrum beta-lactamase |
3 |
|
fatty acids - analysis |
3 |
|
feces |
3 |
|
feces - microbiology |
3 |
|
fever of unknown origin - etiology |
3 |
|
fingers - microbiology |
3 |
|
fishes - microbiology |
3 |
|
gas chromatography-mass spectrometry |
3 |
|
gene expression regulation, bacterial - immunology |
3 |
|
genes, rrna |
3 |
|
genetic variation |
3 |
|
gram-positive bacterial infections - epidemiology - prevention & control |
3 |
|
growth rate |
3 |
|
guideline adherence - organization and administration |
3 |
|
guideline adherence - statistics & numerical data |
3 |
|
hand hygiene |
3 |
|
handwashing - standards |
3 |
|
health services research |
3 |
|
heart failure - epidemiology |
3 |
|
herpes simplex - diagnosis - drug therapy - etiology |
3 |
|
hospitalisation |
3 |
|
hydrolysis |
3 |
|
hygiene - standards |
3 |
|
hygiene practices |
3 |
|
hypervirulent |
3 |
|
immigrant |
3 |
|
immunoglobulin |
3 |
|
immunoglobulin a - administration & dosage - therapeutic use |
3 |
|
immunoglobulin m - administration & dosage - therapeutic use |
3 |
|
immunosuppression |
3 |
|
immunosuppressive agents |
3 |
|
incompatibility groups |
3 |
|
infant, newborn |
3 |
|
infection control - instrumentation - methods - organization and administration - standards |
3 |
|
infectious diseases |
3 |
|
influenza, human - epidemiology |
3 |
|
inh resistance |
3 |
|
injections, intravenous |
3 |
|
international classification of diseases |
3 |
|
katg |
3 |
|
kidney failure, chronic - therapy |
3 |
|
kidney transplantation |
3 |
|
klebsiella pneumoniae - drug effects - enzymology |
3 |
|
klebsiella pneumoniae - enzymology - genetics - isolation & purification |
3 |
|
knowledge |
3 |
|
latent tuberculosis infection |
3 |
|
leukemia, myeloid, acute - diagnosis - therapy |
3 |
|
leukocyte count |
3 |
|
levofloxacin |
3 |
|
long-term care facilities |
3 |
|
lung - microbiology |
3 |
|
lung diseases, fungal - diagnosis - drug therapy - etiology |
3 |
|
maba-inha |
3 |
|
macrolides |
3 |
|
macrophages - immunology - microbiology - secretion |
3 |
|
macrophages - microbiology |
3 |
|
meningitis, pneumococcal - epidemiology - prevention & control |
3 |
|
methicillin |
3 |
|
methicillin - pharmacology |
3 |
|
methicillin-resistant staphylococcus aureus - isolation & purification |
3 |
|
microarray |
3 |
|
microbiology |
3 |
|
mitosporic fungi |
3 |
|
molecular diagnosis |
3 |
|
morbidity |
3 |
|
mouth mucosa - microbiology - pathology |
3 |
|
multidrug-resistant |
3 |
|
multidrug-resistant tuberculosis |
3 |
|
multiple myeloma - complications - diagnosis |
3 |
|
multiple myeloma - complications - immunology |
3 |
|
multiplex allele-specific pcr |
3 |
|
multiplex pcr |
3 |
|
mutation, missense |
3 |
|
mycobacterial rna polymerase |
3 |
|
mycobacteriology |
3 |
|
mycobacterium |
3 |
|
mycobacterium avium complex - chemistry - classification - genetics - isolation & purification |
3 |
|
mycobacterium avium-intracellulare infection - diagnosis |
3 |
|
mycobacterium infections, nontuberculous - drug therapy - surgery |
3 |
|
mycobacterium marinum |
3 |
|
mycobacterium marinum - genetics - metabolism - pathogenicity |
3 |
|
mycobacterium smegmatis |
3 |
|
mycobacterium smegmatis - genetics |
3 |
|
mycobacterium smegmatis - genetics - metabolism - pathogenicity |
3 |
|
mycobacterium tuberculosis - chemistry - classification - genetics - isolation & purification |
3 |
|
mycobacterium tuberculosis - drug effects - isolation & purification |
3 |
|
mycobacterium tuberculosis - genetics - growth and development - isolation and purification - pathogenicity |
3 |
|
mycobacterium tuberculosis - genetics - immunology - isolation & purification - pathogenicity |
3 |
|
mycoses - diagnosis - drug therapy |
3 |
|
ndm-1 |
3 |
|
nosocomial |
3 |
|
nucleic acid hybridization |
3 |
|
ofloxacin - administration & dosage - therapeutic use |
3 |
|
opportunistic infections - diagnosis - drug therapy |
3 |
|
opportunistic infections - diagnosis - drug therapy - etiology |
3 |
|
organizational policy |
3 |
|
oxidoreductases - genetics |
3 |
|
pacbio sequencing |
3 |
|
pathogenicity locus |
3 |
|
pcr |
3 |
|
pentaglobin |
3 |
|
peritoneal dialysis, continuous ambulatory - adverse effects |
3 |
|
peritonitis |
3 |
|
peritonitis - diagnosis - etiology - microbiology |
3 |
|
peritonitis - drug therapy - microbiology |
3 |
|
pharmacoepidemiology |
3 |
|
phylogeny |
3 |
|
pneumococcal disease |
3 |
|
pneumococcal infections - drug therapy - microbiology |
3 |
|
pneumococcal infections - epidemiology - prevention & control |
3 |
|
pneumococcal vaccines - administration & dosage |
3 |
|
pneumonia - epidemiology |
3 |
|
pneumonia - microbiology |
3 |
|
pneumonia, pneumococcal - epidemiology - microbiology |
3 |
|
pneumonia, pneumococcal - epidemiology - prevention & control |
3 |
|
pneumonia, viral - diagnosis - drug therapy - etiology |
3 |
|
postoperative complications - microbiology |
3 |
|
prescriptions - standards |
3 |
|
proactive infection control |
3 |
|
public toilet |
3 |
|
pulmonary disease, chronic obstructive - epidemiology |
3 |
|
pulsed-field gel electrophoresis |
3 |
|
pyrazinamide |
3 |
|
radiography, thoracic |
3 |
|
random allocation |
3 |
|
rapid diagnosis |
3 |
|
rats |
3 |
|
rats, sprague-dawley |
3 |
|
rd207 |
3 |
|
real-time pcr |
3 |
|
renal replacement therapy |
3 |
|
renal transplant recipient |
3 |
|
respiratory diseases |
3 |
|
respiratory specimen |
3 |
|
respiratory tract infections - epidemiology - microbiology |
3 |
|
rflp analysis |
3 |
|
rifampin - pharmacology |
3 |
|
rpob transformation |
3 |
|
rv2820c |
3 |
|
sars virus - isolation & purification |
3 |
|
seasonal influenza |
3 |
|
seasons |
3 |
|
serotype replacement |
3 |
|
severe acute respiratory syndrome - diagnosis - drug therapy |
3 |
|
severe acute respiratory syndrome - radiography - therapy |
3 |
|
shigella flexneri - drug effects - enzymology - isolation & purification |
3 |
|
silicosis |
3 |
|
smoking |
3 |
|
spleen - microbiology |
3 |
|
sputum - cytology - drug effects - immunology - microbiology |
3 |
|
sputum - microbiology |
3 |
|
sputum pathogens |
3 |
|
st414 |
3 |
|
staff education |
3 |
|
staphylococcal infections - drug therapy - microbiology |
3 |
|
staphylococcal skin infections - epidemiology - microbiology |
3 |
|
staphylococcus aureus - drug effects |
3 |
|
staphylococcus lugdunensis |
3 |
|
steroids - adverse effects - therapeutic use |
3 |
|
streptococcal infections - diagnosis - etiology - microbiology |
3 |
|
streptococcus bovis - isolation & purification |
3 |
|
streptococcus pneumoniae - classification - drug effects |
3 |
|
streptococcus pneumoniae - classification - drug effects - immunology - isolation and purification |
3 |
|
streptococcus pneumoniae - drug effects - isolation & purification |
3 |
|
surveillance |
3 |
|
survival rate |
3 |
|
susceptible exposed infectious recovered (seir) model |
3 |
|
swine origin influenza virus a/h1n1 |
3 |
|
synovial membrane - surgery |
3 |
|
thermus thermophilus - genetics |
3 |
|
tomography, x-ray computed |
3 |
|
tongue - microbiology - pathology |
3 |
|
treatment |
3 |
|
trehalose repressor |
3 |
|
tuberculosis - diagnosis |
3 |
|
tuberculosis - microbiology |
3 |
|
tuberculosis, splenic - complications - diagnosis - drug therapy |
3 |
|
vaccination rate |
3 |
|
vaccines, conjugate - administration & dosage |
3 |
|
vancomycin-resistant enterococcus faecium |
3 |
|
vancomycin-resistant staphylococcus aureus |
3 |
|
virulence |
3 |
|
young adult |
3 |
|
acetamides - pharmacology |
2 |
|
acinetobacter baumannii - classification - drug effects - isolation & purification |
2 |
|
acinetobacter baumannii - drug effects |
2 |
|
acinetobacter infections - epidemiology - microbiology |
2 |
|
aeromonas hydrophila - drug effects - growth & development - isolation & purification |
2 |
|
age distribution |
2 |
|
air microbiology |
2 |
|
air movements |
2 |
|
air pollutants |
2 |
|
air pollution, indoor |
2 |
|
amino acid substitution |
2 |
|
aminoglycoside resistance |
2 |
|
anti-bacterial agents - adverse effects - therapeutic use |
2 |
|
anti-bacterial agents - chemical synthesis - pharmacology |
2 |
|
anti-bacterial agents - chemistry |
2 |
|
anti-bacterial agents - chemistry - pharmacology |
2 |
|
anti-infective agents - pharmacology - therapeutic use |
2 |
|
antibiotic class |
2 |
|
antibiotic resistance genes |
2 |
|
arthritis, infectious |
2 |
|
aspergillosis - diagnosis - epidemiology - prevention & control |
2 |
|
aspergillus |
2 |
|
bacteremia - diagnosis - drug therapy - epidemiology |
2 |
|
bacteremia - drug therapy - microbiology |
2 |
|
bacterial capsules |
2 |
|
bacterial contamination |
2 |
|
bacteroides |
2 |
|
bacteroides dorei |
2 |
|
bacteroides fragilis |
2 |
|
bacteroides thetaoiotaomicron |
2 |
|
benzoic acids - adverse effects - pharmacology |
2 |
|
beta-lactamases - analysis |
2 |
|
beta-lactamases - chemistry |
2 |
|
beta-lactamases - chemistry - genetics - metabolism |
2 |
|
beta-lactamases - classification - genetics - metabolism |
2 |
|
beta-lactamases - secretion |
2 |
|
binding, competitive |
2 |
|
biological transport |
2 |
|
blood donation |
2 |
|
blood transfusion |
2 |
|
bloodstream infections |
2 |
|
blotting, southern |
2 |
|
bone marrow |
2 |
|
bronchiectasis - diagnosis - enzymology |
2 |
|
bronchiectasis elastase |
2 |
|
calorimetry, differential scanning |
2 |
|
carbapenems |
2 |
|
carbuncle - microbiology |
2 |
|
catalysis |
2 |
|
cefotaximases |
2 |
|
cefotaxime resistance |
2 |
|
cefoxitin |
2 |
|
cephalosporins - pharmacology |
2 |
|
chlorhexidine |
2 |
|
ciprofloxacin - pharmacology |
2 |
|
circular dichroism |
2 |
|
clarithromycin |
2 |
|
clarithromycin - pharmacology |
2 |
|
clinical effectiveness |
2 |
|
clinical feature |
2 |
|
clostridium infections - epidemiology - etiology |
2 |
|
colchicine |
2 |
|
colchicine - poisoning |
2 |
|
colony-forming units assay |
2 |
|
combined modality therapy |
2 |
|
communicable disease control |
2 |
|
communicable diseases - transmission |
2 |
|
community-acquired infections - epidemiology - microbiology - transmission |
2 |
|
comorbidity |
2 |
|
compartment model |
2 |
|
confidence intervals |
2 |
|
contact screening |
2 |
|
cough |
2 |
|
cross-sectional studies |
2 |
|
ctx-m beta-lactamase |
2 |
|
debridement - methods |
2 |
|
deep learning |
2 |
|
deferasirox (dfra) |
2 |
|
deferiprone (l1) |
2 |
|
deferoxamine - adverse effects - pharmacology |
2 |
|
desferrioxamine (dfo) |
2 |
|
diabetes complications |
2 |
|
diabetes mellitus - immunology |
2 |
|
diarrhea - microbiology |
2 |
|
diarrhoea |
2 |
|
dimerization |
2 |
|
disease outbreaks - history |
2 |
|
disease transmission, infectious |
2 |
|
disease-free survival |
2 |
|
dna fingerprinting - methods |
2 |
|
dna probes |
2 |
|
droplet evaporation |
2 |
|
droplet movement |
2 |
|
drug resistance in microorganisms. |
2 |
|
drug resistance, microbial - genetics |
2 |
|
drug resistance, microbial - genetics - physiology |
2 |
|
drug resistance, multiple |
2 |
|
drug synergism |
2 |
|
drug-drug interactions |
2 |
|
e. coli |
2 |
|
enteral nutrition |
2 |
|
enterobacteriaceae - drug effects - enzymology |
2 |
|
escherichia coli - classification - drug effects - genetics - isolation & purification |
2 |
|
escherichia coli - drug effects - enzymology - genetics - isolation & purification |
2 |
|
escherichia coli - enzymology - growth & development |
2 |
|
escherichia coli infections - diagnosis - drug therapy - epidemiology |
2 |
|
escherichia coli proteins - genetics |
2 |
|
escherichia coli proteins - genetics - metabolism |
2 |
|
etiology |
2 |
|
exhalation |
2 |
|
extremities - surgery |
2 |
|
family characteristics |
2 |
|
family health |
2 |
|
fascia - pathology - surgery |
2 |
|
fasciitis - complications - microbiology |
2 |
|
fasciitis, necrotizing - etiology |
2 |
|
fasciitis, necrotizing - pathology - surgery |
2 |
|
fatality |
2 |
|
fluoroquinolone resistance |
2 |
|
fluoroquinolones - adverse effects - therapeutic use |
2 |
|
fosfomycin resistance |
2 |
|
gene cassettes |
2 |
|
gene mobility |
2 |
|
glycopeptides |
2 |
|
gout suppressants - poisoning |
2 |
|
gram-negative bacterial infections - chemically induced - epidemiology |
2 |
|
gram-positive bacterial infections - microbiology |
2 |
|
h. influenzae |
2 |
|
h58 |
2 |
|
haemophilus infections - epidemiology - microbiology |
2 |
|
hand disinfection |
2 |
|
health facilities |
2 |
|
health-seeking behavior |
2 |
|
history, 20th century |
2 |
|
homes for the aged |
2 |
|
hotel |
2 |
|
human immunodeficiency virus |
2 |
|
humidity |
2 |
|
hydrogel - chemical synthesis - chemistry |
2 |
|
hydrogels - chemistry |
2 |
|
hydrogen bonding |
2 |
|
ifn-γ release assay |
2 |
|
imipenem - pharmacology |
2 |
|
imipenem resistance |
2 |
|
immunocompromised patient |
2 |
|
infection transmission |
2 |
|
inflammation mediators - metabolism |
2 |
|
influenza, human - epidemiology - history - mortality |
2 |
|
integrons |
2 |
|
interferon-gamma release assay |
2 |
|
interleukin |
2 |
|
iron chelating agents - adverse effects - pharmacology |
2 |
|
iron overload - drug therapy - microbiology |
2 |
|
kinetics |
2 |
|
klebsiella - enzymology - growth & development |
2 |
|
klebsiella infections |
2 |
|
klebsiella infections - chemically induced - epidemiology |
2 |
|
klebsiella pneumoniae - drug effects - genetics - isolation & purification |
2 |
|
klebsiella pneumoniae - drug effects - growth & development - isolation & purification |
2 |
|
klebsiella species |
2 |
|
large droplet |
2 |
|
leg injuries - complications - therapy |
2 |
|
length of stay |
2 |
|
leukemia |
2 |
|
leukotriene |
2 |
|
lincosamides - pharmacology |
2 |
|
liver cirrhosis |
2 |
|
liver cirrhosis - etiology |
2 |
|
lupus erythematosus, systemic - complications |
2 |
|
macrolide resistance |
2 |
|
macrolides - pharmacology |
2 |
|
macromolecular substances - chemical synthesis - chemistry |
2 |
|
magnetic resonance spectroscopy |
2 |
|
mass screening |
2 |
|
media |
2 |
|
meningitis, bacterial - epidemiology - microbiology - transmission |
2 |
|
methicillin resistance - drug effects - genetics |
2 |
|
methicillin resistance and meca gene |
2 |
|
methicillin-resistant staphylococcus aureus - classification - genetics - isolation & purification |
2 |
|
methicillin-resistant staphylococcus aureus - genetics - isolation & purification |
2 |
|
metronidazole resistance |
2 |
|
microscopy, electron |
2 |
|
models, molecular |
2 |
|
models, theoretical |
2 |
|
molecular conformation |
2 |
|
mortality |
2 |
|
multivariate analysis |
2 |
|
mycobacterium tuberculosis - isolation & purification |
2 |
|
nasal cavity - microbiology |
2 |
|
non-tuberculous mycobacteria |
2 |
|
nutrition disorders - immunology |
2 |
|
organoplatinum compounds - chemical synthesis - pharmacology |
2 |
|
osteomyelitis |
2 |
|
oxacillin agar screening method |
2 |
|
oxacillin resistance |
2 |
|
oxazolidinones - pharmacology |
2 |
|
pancreatic elastase - blood |
2 |
|
pandemic |
2 |
|
panton-valentine leukocidin |
2 |
|
patient admission |
2 |
|
penicillins - pharmacology |
2 |
|
platelet transfusion - adverse effects |
2 |
|
pleural empyema |
2 |
|
pneumococcal infections - drug therapy - epidemiology - microbiology |
2 |
|
prognosis |
2 |
|
public health |
2 |
|
pyrenes - chemistry |
2 |
|
pyridones - adverse effects - pharmacology |
2 |
|
quarantine |
2 |
|
questionnaires |
2 |
|
recurrence |
2 |
|
reoperation |
2 |
|
resistance plasmid |
2 |
|
resistant mechanism |
2 |
|
respiratory infections |
2 |
|
respiratory jet |
2 |
|
rifampicin |
2 |
|
risk |
2 |
|
s. aureus |
2 |
|
salmonella |
2 |
|
salmonella enteritidis - isolation & purification |
2 |
|
salmonella infections - microbiology |
2 |
|
salmonella typhi |
2 |
|
salmonella typhimurium - isolation & purification |
2 |
|
sccmec |
2 |
|
screening methods |
2 |
|
selective medium |
2 |
|
sensitivity |
2 |
|
sepsis - microbiology |
2 |
|
sex distribution |
2 |
|
shigella flexneri - drug effects - enzymology - genetics - isolation & purification |
2 |
|
shock, septic - etiology |
2 |
|
skates (fish) |
2 |
|
skin - microbiology |
2 |
|
skin disinfection |
2 |
|
sneezing |
2 |
|
sodium chloride |
2 |
|
soft tissue infections - epidemiology - microbiology - transmission |
2 |
|
spain - epidemiology |
2 |
|
specificity |
2 |
|
spectrometry, fluorescence |
2 |
|
spectrometry, mass, electrospray ionization |
2 |
|
sputum - enzymology |
2 |
|
staphylococcal infections - drug therapy - epidemiology - microbiology |
2 |
|
staphylococcal infections - epidemiology - microbiology - prevention & control |
2 |
|
staphylococcal infections - epidemiology - microbiology - transmission |
2 |
|
staphylococcal protein a - genetics |
2 |
|
staphylococcal skin infections - epidemiology - microbiology - transmission |
2 |
|
staphylococci |
2 |
|
staphylococcus aureus - drug effects - genetics |
2 |
|
staphylococcus aureus - drug effects - isolation & purification |
2 |
|
streptococcus agalactiae - isolation & purification - pathogenicity |
2 |
|
streptococcus pneumoniae - classification - drug effects - genetics |
2 |
|
streptococcus pneumoniae - drug effects - genetics - metabolism |
2 |
|
streptococcus pneumoniae - isolation & purification |
2 |
|
streptococcus pneumoniae. |
2 |
|
streptogramins - pharmacology |
2 |
|
strongyloides stercoralis |
2 |
|
strongyloidiasis - immunology |
2 |
|
structure-activity relationship |
2 |
|
sulfamethoxazole - pharmacology |
2 |
|
susceptibility test comparison |
2 |
|
systemic lupus erythematosus |
2 |
|
terminology as topic |
2 |
|
thalassemia |
2 |
|
thalassemia - drug therapy - microbiology |
2 |
|
thermodynamics |
2 |
|
thoracic medicine |
2 |
|
trans-activators - genetics |
2 |
|
transmission |
2 |
|
triazoles - adverse effects - pharmacology |
2 |
|
trimethoprim - pharmacology |
2 |
|
tuberculin skin test |
2 |
|
tuberculosis, pulmonary - diagnosis - drug therapy |
2 |
|
tuberculosis, pulmonary - drug therapy - epidemiology |
2 |
|
typhoid fever |
2 |
|
urinary tract infections |
2 |
|
urinary tract infections - epidemiology - microbiology |
2 |
|
urine - microbiology |
2 |
|
vancomycin - analogs & derivatives - chemical synthesis - pharmacology |
2 |
|
vancomycin - analogs & derivatives - chemistry |
2 |
|
vancomycin - analogs & derivatives - chemistry - pharmacology |
2 |
|
ventilation system |
2 |
|
vibrio infections - complications - diagnosis - therapy |
2 |
|
vital capacity - physiology |
2 |
|
water |
2 |
|
water - chemistry |
2 |
|
wound infection - epidemiology - microbiology |
2 |
|
x-ray diffraction |
2 |
|
xdr |
2 |
|
2-propanol - pharmacology |
1 |
|
acinetobacter baumannii - isolation & purification |
1 |
|
acinetobacter infections - drug therapy |
1 |
|
acinetobacter infections - drug therapy - epidemiology - microbiology |
1 |
|
agar |
1 |
|
aids-related opportunistic infections - microbiology |
1 |
|
airway management |
1 |
|
alloys |
1 |
|
amoxicillin-clavulanate |
1 |
|
amoxicillin-potassium clavulanate combination - pharmacology |
1 |
|
ampicillin - pharmacology |
1 |
|
ampicillin- sulbactam |
1 |
|
ampicillin-sulbactam |
1 |
|
amr |
1 |
|
anaerobiosis |
1 |
|
anti-infective agents - administration & dosage |
1 |
|
antigens, bacterial |
1 |
|
arm |
1 |
|
arteriovenous malformations - complications - diagnosis - therapy |
1 |
|
atopic dermatitis |
1 |
|
bacteria - drug effects - enzymology - isolation and purification |
1 |
|
bacteria - growth & development |
1 |
|
bacteria - growth & development - isolation & purification |
1 |
|
bacterial infections - microbiology |
1 |
|
bacterial infections - prevention & control - transmission |
1 |
|
bacterial toxins - biosynthesis |
1 |
|
birds |
1 |
|
blood - microbiology |
1 |
|
blood donors |
1 |
|
blood platelets - microbiology |
1 |
|
blood preservation |
1 |
|
blood specimen collection |
1 |
|
bordetella bronchiseptica |
1 |
|
brain abscess - complications - diagnosis |
1 |
|
ceftazidime - pharmacology |
1 |
|
cells, cultured |
1 |
|
cetrimonium compounds - pharmacology |
1 |
|
clinical features |
1 |
|
clinical laboratory standards institute |
1 |
|
clsi |
1 |
|
communicable diseases, emerging - diagnosis - drug therapy - epidemiology |
1 |
|
communicable diseases, emerging - epidemiology - prevention & control |
1 |
|
communicable diseases, emerging - prevention & control |
1 |
|
community-acquired infections - drug therapy - epidemiology - microbiology |
1 |
|
community-acquired methicillin-resistant staphylococcus aureus (ca-mrsa) |
1 |
|
community-acquired mrsa |
1 |
|
community-associated methicillin-resistant staphylococcus aureus |
1 |
|
comparative genomics |
1 |
|
copy number variation |
1 |
|
cross infection |
1 |
|
cross infection - prevention & control |
1 |
|
ctx-m β-lactamases |
1 |
|
cystitis |
1 |
|
developed countries |
1 |
|
developing countries |
1 |
|
diarrhea |
1 |
|
disease transmission, infectious - prevention & control |
1 |
|
disinfectants - pharmacology |
1 |
|
disinfection - methods |
1 |
|
diversity |
1 |
|
drug evaluation |
1 |
|
drug therapy, combination - pharmacology |
1 |
|
drug utilization review - organization & administration |
1 |
|
eczema |
1 |
|
enterobacteriaceae - drug effects - isolation & purification |
1 |
|
enterococcus - drug effects - isolation & purification |
1 |
|
environmental monitoring |
1 |
|
escherichia coli - drug effects |
1 |
|
ethnic groups |
1 |
|
eucast |
1 |
|
european committee on antimicrobial susceptibility testing |
1 |
|
evolution |
1 |
|
exotoxins - biosynthesis |
1 |
|
extremely low birth weight |
1 |
|
genetics |
1 |
|
genomics |
1 |
|
gram-negative bacteria - drug effects - isolation & purification |
1 |
|
guideline adherence - organization & administration |
1 |
|
haemophilus influenzae glpq protein |
1 |
|
handwashing |
1 |
|
haplotypes |
1 |
|
hiv infections - epidemiology - prevention & control - transmission |
1 |
|
hospital-acquired pneumonia |
1 |
|
iga deficiency - complications |
1 |
|
igg deficiency - complications |
1 |
|
immunotherapy - methods |
1 |
|
in vitro susceptibility |
1 |
|
infection control |
1 |
|
infection prevention and control |
1 |
|
infections |
1 |
|
infectious disease |
1 |
|
infectious disease transmission, patient-to-professional - prevention & control - statistics & numerical data |
1 |
|
influenza in birds - epidemiology - transmission |
1 |
|
influenza, human - epidemiology - prevention & control |
1 |
|
intensive care units |
1 |
|
iron - chemistry |
1 |
|
isoelectric focusing |
1 |
|
klebsiella - drug effects |
1 |
|
kpc β-lactamases |
1 |
|
leukocidins - biosynthesis |
1 |
|
liver diseases - microbiology |
1 |
|
lung diseases - epidemiology - microbiology |
1 |
|
lung diseases, fungal - microbiology |
1 |
|
lung diseases, obstructive - epidemiology - microbiology |
1 |
|
lungs |
1 |
|
magnetics |
1 |
|
mdr |
1 |
|
meningitis |
1 |
|
mers |
1 |
|
microbial viability |
1 |
|
nanotechnology - methods |
1 |
|
ndm1 |
1 |
|
neonatal intensive care unit |
1 |
|
neonate |
1 |
|
newborn/infants |
1 |
|
occupation |
1 |
|
occupational diseases - epidemiology - prevention & control |
1 |
|
occupational exposure - adverse effects |
1 |
|
optical mapping |
1 |
|
outpatients |
1 |
|
particle size |
1 |
|
patient discharge |
1 |
|
patient isolation |
1 |
|
penicillium - isolation & purification |
1 |
|
pfge |
1 |
|
pharmacy service, hospital - standards |
1 |
|
platelet concentrates |
1 |
|
plateletpheresis |
1 |
|
platinum - chemistry |
1 |
|
pneumococcal |
1 |
|
pneumonia - drug therapy - microbiology |
1 |
|
pneumonia, bacterial - epidemiology - microbiology |
1 |
|
pneumonia, bacterial - epidemiology - microbiology - transmission |
1 |
|
pneumonia, pneumococcal - drug therapy |
1 |
|
population structure |
1 |
|
povidone-iodine - pharmacology |
1 |
|
prescriptions, drug |
1 |
|
preterm |
1 |
|
prevention |
1 |
|
pulmonary artery - abnormalities |
1 |
|
quarantine - organization & administration |
1 |
|
radiology |
1 |
|
recombination |
1 |
|
respiration, artificial - adverse effects |
1 |
|
respiratory tract infections - epidemiology - prevention & control |
1 |
|
rna-seq |
1 |
|
sars |
1 |
|
sars virus - physiology |
1 |
|
sepsis |
1 |
|
severe acute respiratory syndrome - diagnosis - drug therapy - epidemiology |
1 |
|
severe acute respiratory syndrome - drug therapy - epidemiology - prevention & control |
1 |
|
severe acute respiratory syndrome - epidemiology - prevention & control - transmission |
1 |
|
severe acute respiratory syndrome - epidemiology - transmission - virology |
1 |
|
severe acute respiratory syndrome - prevention & control |
1 |
|
shigella - drug effects |
1 |
|
silver staining |
1 |
|
single-molecule analysis |
1 |
|
skin and soft tissue infections |
1 |
|
soft tissue infections - epidemiology - microbiology |
1 |
|
st8 ca-mrsa/j |
1 |
|
staphylococcal infections - drug therapy |
1 |
|
staphylococcus - drug effects - isolation & purification |
1 |
|
staphylococcus aureus - classification - drug effects - genetics - isolation & purification |
1 |
|
staphylococcus aureus - drug effects - physiology |
1 |
|
streptococcal infections - epidemiology - microbiology |
1 |
|
streptococcus bovis |
1 |
|
streptococcus pyogenes - classification - drug effects - isolation & purification |
1 |
|
sulbactam - pharmacology |
1 |
|
survival analysis |
1 |
|
susceptibility testing methods |
1 |
|
taiwan - epidemiology |
1 |
|
toxic shock syndrome toxin-1 (tsst-1) |
1 |
|
triage |
1 |
|
ultrasonography |
1 |
|
urinary |
1 |
|
urinary bladder |
1 |
|
whole genome sequencing |
1 |
|
whole-genome sequencing |
1 |
|
world health |
1 |
|
β-lactamase |
1 |
